ProfileGDS4814 / ILMN_1706652
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 65% 71% 62% 68% 69% 69% 64% 67% 69% 70% 69% 66% 70% 70% 69% 70% 65% 71% 68% 71% 66% 66% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)61.156465
GSM780708Untreated after 4 days (C2_1)77.369271
GSM780709Untreated after 4 days (C3_1)57.089762
GSM780719Untreated after 4 days (C1_2)68.017168
GSM780720Untreated after 4 days (C2_2)71.371869
GSM780721Untreated after 4 days (C3_2)70.959869
GSM780710Trastuzumab treated after 4 days (T1_1)59.103964
GSM780711Trastuzumab treated after 4 days (T2_1)65.583767
GSM780712Trastuzumab treated after 4 days (T3_1)69.135169
GSM780722Trastuzumab treated after 4 days (T1_2)71.802370
GSM780723Trastuzumab treated after 4 days (T2_2)71.534369
GSM780724Trastuzumab treated after 4 days (T3_2)63.554866
GSM780713Pertuzumab treated after 4 days (P1_1)72.102170
GSM780714Pertuzumab treated after 4 days (P2_1)74.393970
GSM780715Pertuzumab treated after 4 days (P3_1)70.809869
GSM780725Pertuzumab treated after 4 days (P1_2)73.90970
GSM780726Pertuzumab treated after 4 days (P2_2)61.297265
GSM780727Pertuzumab treated after 4 days (P3_2)77.562871
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)68.389168
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)75.14371
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)63.435166
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)63.085966
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)61.546665